论文部分内容阅读
目的观察紫杉醇+顺铂方案联合同步放疗治疗中晚期食管癌临床疗效。方法选取2011年1月-2012年12月收治的中晚期食管癌患者120例,随机分为研究组与对照组各60例,对照组予以单纯放疗,研究组则予以紫杉醇+顺铂方案联合同步放疗,分析对比2组患者治疗效果、不良反应发生率及1年生存率。结果研究组总有效率为90.0%明显高于对照组的63.3%,1年生存率为76.7%高于对照组的50.0%,差异均有统计学意义(P<0.05)。2组不良反应发生率差异无统计学意义(P>0.05)。结论紫杉醇+顺铂方案联合同步放疗治疗中晚期食管癌患者效果明显,有效改善预后质量。
Objective To observe the clinical efficacy of paclitaxel + cisplatin combined with concurrent radiotherapy in the treatment of advanced esophageal cancer. Methods A total of 120 patients with advanced esophageal cancer who were admitted to our hospital from January 2011 to December 2012 were randomly divided into study group and control group, with 60 cases in each group. The control group received radiotherapy alone and the study group was treated with paclitaxel plus cisplatin combination Radiotherapy, analysis of two groups of patients treated with treatment, adverse reactions and 1-year survival rate. Results The total effective rate was 90.0% in the study group and 63.3% in the control group. The 1-year survival rate was 76.7% in the study group, which was significantly higher than that in the control group (50.0%, P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion paclitaxel + cisplatin combined with concurrent radiotherapy in patients with advanced esophageal cancer effect is obvious, effectively improve the quality of prognosis.